IKT NASDAQ
Inhibikase Therapeutics, Inc.
1W: -6.5%
1M: -4.4%
3M: -1.1%
YTD: -10.8%
1Y: -12.6%
3Y: -55.5%
5Y: -93.7%
$1.69
-0.05 (-2.87%)
Weekly Expected Move ±9.0%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q3 20231
Institutions Holding
-16 vs prior
0.0%
Ownership
-0.04%
0
New
0
Increased
1
Reduced
1
Closed
👔 Insider Trades
7 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-21 | Aurentz Vincent | director | D-Sale to Issuer | 255,299 | $— | $0 | Filing |
| 2026-02-21 | Cabell Christopher | officer: president & head of r&d | D-Sale to Issuer | 338,282 | $— | $0 | Filing |
| 2026-02-21 | Munshi Amit | director | D-Sale to Issuer | 19,089 | $— | $0 | Filing |
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10% owner | P-Purchase | 2,068,965 | $1.45 | $3.0M | Filing |
| 2025-11-21 | Sands Capital Alternatives, LLC | 10% owner | P-Purchase | 2,068,965 | $1.45 | $3.0M | Filing |
| 2025-11-21 | SANDS FRANK M. | 10% owner | P-Purchase | 2,068,965 | $1.45 | $3.0M | Filing |
| 2025-02-21 | Munshi Amit | director | A-Grant/Award | 57,265 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
1 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| HAMILTON LANE ADVISORS LLC | 0 | $0K | -13,802 | 2023-09-30 | Filing |